MedTrace Logo

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

NCT00080236 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2012-08-10

No results posted yet for this study

Summary

The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period.

Conditions

  • Liver Transplantation
  • Hepatitis
  • Cholestasis
  • Carcinoma, Hepatocellular

Interventions

DRUG

IDN-6556

DRUG

Placebo

Sponsors & Collaborators

  • Idun Pharmaceuticals

    collaborator INDUSTRY

  • Conatus Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00080236 on ClinicalTrials.gov